Diagnostic radioisotopes are radioactive isotopes or molecules labeled with radioisotopes that are widely used for diagnostic procedures in nuclear medicine to diagnose and evaluate medical conditions. They produce gamma rays that can be detected by Geiger-Müller tube, scintillation counter or camera that helps in imaging organs and tissues. Technetium-99m (Tc-99m) and Fluorine-18 (F-18) are examples of diagnostic radioisotopes commonly used in Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scans respectively. SPECT and PET scans provide 3D images of internal organs and tissues and help physicians to diagnose, stage and monitor treatment of cancers, heart diseases and brain disorders.

The global diagnostic radioisotopes market is estimated to be valued at US$ 6.54 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics
Rising prevalence of chronic diseases such as cancer, cardiovascular diseases and neurological disorders is driving the growth of the diagnostic radioisotopes market size. According to the statistics by World Health Organization (WHO), cancer burden has risen to 19.3 million new cases and 10 million cancer deaths in 2020. Growing geriatric population prone to age-related diseases is also fueling the market growth. Diagnostic radioisotopes help doctors to precisely diagnose chronic diseases at early stages and guide them for effective treatment planning. This reduces healthcare costs associated with late stage diagnoses and multiple diagnostic tests. Advancements in radioisotope production technologies by key players are further propelling the market growth.

SWOT Analysis

Strength: The diagnostic radioisotopes market has high growth potential due to the increasing prevalence of chronic diseases like cancer. The rising awareness regarding early diagnosis and preventive healthcare further strengthens the market. In addition, continued technological advancements in isotopes production and imaging technologies boost the market growth.

Weakness: Stringent regulations pertaining to the production, transportation and usage of radioisotopes act as a major restraint for market players. High costs associated with isotopes production and short half-lives of various isotopes pose challenges.

Opportunity: Rising geriatric population vulnerable to chronic diseases creates demand for advanced diagnostic procedures. Untapped potential in developing regions offers lucrative opportunities. Further, development of alpha particle emitters for cancers treatment opens new avenues.

Threats: Alternative imaging modalities like MRIs and CT scans taking away market share from radioisotopes. Supply constraints due to disruption in production during COVID-19 pandemic threaten market growth. Stringent norms regarding radiation safety and disposal of radioactive wastes limit market expansion.

Key Takeaways

The global diagnostic radioisotopes market is expected to witness high growth over the forecast period. The global diagnostic radioisotopes market is estimated to be valued at US$ 6.54 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2031.

Regional analysis related content comprises: North America represents the largest as well as the most profitable market for diagnostic radioisotopes currently. Major factors influencing growth include robust research funding, availability of novel isotopes and advanced diagnostic technologies. However, Asia Pacific region is poised to grow at highest CAGR between 2024 to 2031 backed by rising healthcare expenditures in China and India. Countries in the region are investing heavily in nuclear medicine infrastructure to address treatment needs of growing patient pool. For instance, India plans to establish over 100 nuclear medicine centers by 2030.

Key players related content comprises: Key players operating in the diagnostic radioisotopes market are Johnson & Johnson, Mueller Sports Medicine, 3M Company, KT Tape, Medco Athletics, Nitto Denko Corporation, Andover Healthcare Inc., Medline Industries, Inc. These players are focusing on new product launches, collaborations and geographic expansions to strengthen their positions in the market. For instance, Nitto Denko Corporation launched new kinesiology tape products specifically designed for athletes in 2020.

Get more insights on this topic: https://www.trendingwebwire.com/diagnostic-radioisotopes-market-size-and-outlook/